Selskabets formål er at drive handel,service og industri
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 996.2 mio. | -19.4 mio. | 3.2 mia. | 2.6 mia. | 757 | |
CVR: 20896949
Previous names: A/S PSE 38 NR. 1936
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB resigned as auditor
Oluf Riddersholm joined as director
Andreas Morthorst left as director
Compared to 52 companies in Fremstilling af bestrålingsudstyr og elektromedicinsk og elektroterapeutisk udstyr
Comparison is based on industry median values
The financial health of ELLAB A/S shows signs of volatility, particularly with a significant loss of 19.4 million DKK in 2024 following a profitable 2023, where the company reported a profit of 131.1 million DKK on revenues of 858.2 million DKK. Revenue has been on an upward trajectory, increasing from 497.2 million DKK in 2021 to 996.2 million DKK in 2024, indicating strong growth potential. However, the recent dip in profitability raises concerns about operational efficiency and margin stability. With equity standing at a robust 2.59 billion DKK, the company maintains a solid financial foundation, positioning itself favorably within the manufacturing sector of radiation and medical equipment.
AI-generated summary
companydata.dk